News

Iptacopan has the potential to address an unmet need in PNH by significantly increasing hemoglobin levels in patients who remain anemic, fatigued and dependent on blood transfusions after anti-C5 treatment.

Falloon presented new data at ACG 2022 on identifying biomarkers for pouch inflammation.

Patients with NAFLD were more likely to have comorbidities, including diabetes, hypertension, chronic respiratory disease, hypothyroidism, chronic kidney disease, sleep apnea, and hyperlipidemia.

A 30 mg dose of upadacitinib led to a 1 month longer clinical remission and approximately 20% of patients had less severe disease at 52 weeks, when compared with a 15 mg dose for patients with active ulcerative colitis.

In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the ongoing GLP-1 RA shortage and whether or not celebrities using these agents for weight loss is a real issue in the community as well as provide insight into their top takeaways from the ADA/KDIGO consensus report.

The rate of serious infections was 5.9 events per 100 person-years in the placebo group, compared to 5.0 events in the upadacitinib 15 mg cohort and 3.2 upadacitinib 30 mg group.

In data presented during ACG, investigators found patients with malnutrition and CDI had higher mortality and increased hospitals costs compared to those without malnutrition.

In consideration of emerging JAK inhibitor options, and the current prescribing availability of baricitinib.

New open-label extension data support the long-term use of the systemic therapy in patients with moderate-to-severe disease.

Bezlotoxumab is a fully humanized monoclonal antibody approved by the US Food and Drug Administration in 2017 for the prevention of recurrent CDI.

Brett King, MD, PhD, explains the altered screening and care strategies for patients following baricitinib's approval.

Real-world analysis comparing systemic therapies show dupilumab better improves EASI and quality of life among affected children.

Brett King, MD, PhD, discusses the newly available JAK inhibitor—the first systemic therapy approved for the hair-loss condition.

Data from the ongoing TARGET-DERM AM observational study show patients with more exposed disease have generally worse severity and challenges linked to quality of life.

The recent GUIDE study examined the efficacy of guselkumab for moderate-to-severe plaque psoriasis, finding it consistent with previous trials.

The moisturizer was designed to address concerns regarding the suitability of sunscreens for individuals with skin of color and show the importance of "aesthetic elegance” to increase sunscreen utilization.

The JAK inhibitor received FDA approval for vitiligo this summer. Investigator now see it as a potent non-steroidal option for eczema.

Christopher Bunick, MD, discusses the future progress of acne management—including a potential mRNA vaccine current in development.

New 16-week data from the SPROUT trial show the PDE4 inhibitor may be highly efficacious in chilren and adolescents.

The novel OX40 inhibitor showed significant efficacy in 4 different doses versus placebo in Fall Clinical Dermatology data.

With a broadening array of drug options, involving patients in the care process may be a key to adherence and long-term success.

Recent phase 3 trial results suggest positive effects and faster onset using CAL/BDP cream for adult plaque psoriasis.

Pooled data from 7 clinical trials show the IL-23 inhibitor is not associated with worsened risk of adverse events or infections.

Christopher Bunick, MD, PhD, reviews the benefit of antibiotic resistance, blood-brain barrier penetration, and digestive distress with agents like sarecycline.

Dermatologists and primary care physicians believe there is a significant unmet need for treatments for patients with mild or moderate atopic dermatitis.

Peter Lio, MD, shares his strategy for advancing severely impacted patients from systemic therapy to either upadacitinib or abrocitinib.

A discussion regarding the use of plaque psoriasis treatments such as apremilast, ixekizumab, and methotrexate.

A dermatologist considers what the orally-administered TYK2 inhibitor will provide eligible adult patients.